stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Shares outstanding
Summit Therapeutics PLC's shares outstanding at the end of fiscal 2025 was $747.7M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $778.2M. Over the past ten years it has ranged from $7.9M (fiscal 2015) to $747.7M (fiscal 2025) — the current reading is the highest in ten years. Summit Therapeutics PLC ranks 3rd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $747.7M | 4.06% |
| FY2024 | $718.5M | 15.96% |
| FY2023 | $619.6M | 220.50% |
| FY2022 | $193.3M | 46.78% |
| FY2021 | $131.7M | 89.45% |
| FY2020 | $69.5M | 111.78% |
| FY2019 | $32.8M | 90.55% |
| FY2019 | $17.2M | 31.65% |
| FY2018 | $13.1M | (93.75%) |
| FY2017 | $209.3M | 1,600.21% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $778.2M | 0.35% |
| Mar 2026 | $775.5M | 3.71% |
| Dec 2025 | $747.7M | 0.58% |
| Sep 2025 | $743.4M | 0.11% |
| 44 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SMMT Summit Therapeutics PLC | $778.2M |
| BBIO BridgeBio Pharma, Inc. compare | $196.0M |
| BMRN BioMarin Pharmaceutical Inc. compare | $193.6M |
| TECH Bio-Techne Corp compare | $157.0M |
| PCVX Vaxcyte, Inc. compare | $144.5M |
| HALO Halozyme Therapeutics, Inc. compare | $122.6M |
| KYMR Kymera Therapeutics, Inc. compare | $100.1M |
| ASND Ascendis Pharma A/S compare | $68.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $64.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement